Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers, Exosomes & Liquid Biopsy Europe 2020

Circulating Biomarkers, Exosomes & Liquid Biopsy Europe 2020 Agenda


Print Agenda

Monday, 19 October 2020

00:00

Valérie TalyKeynote Presentation

Title to be Confirmed.
Valérie Taly, CNRS Research Director, Group leader Translational Research and Microfluidics, University Paris Descartes, France

00:00

Steve SoperKeynote Presentation

Title to be Confirmed.
Steve Soper, Foundation Distinguished Professor, Director, Center of BioModular Multi-scale System for Precision Medicine, The University of Kansas, Adjunct Professor, Ulsan National Institute of Science & Technology, United States of America

00:00

Title to be Confirmed.
Michiel Pegtel, Associate Professor, Cancer Center Amsterdam, VU University Medical Center, Netherlands

00:00

Title to be Confirmed.
Andries Zijlstra, Associate Professor of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, United States of America

00:00

Are Extracellular Vesicles In Liquid Biopsies the Source of My Signals?
Edwin van der Pol, Assistant Professor, Amsterdam University Medical Center, Netherlands

To discover new biomarkers in blood plasma, bulk assays are frequently applied after particle isolation. Particles of interest include extracellular vesicles (EVs), EV-associated miRNA, and circulating cell-free DNA. Blood plasma, however, is a complex body fluid that contains many other particles, such as lipoprotein particles, protein aggregates, and residual platelets, which may have similar physical properties. Therefore, isolation methods neither enrich nor recover 100% over the particles of interest. Moreover, signals of bulk assays do not necessarily originate from the particles of interest. By combining physical models with new isolation methods and a flow cytometer of which all aspects are calibrated, we gained new insights in the efficacy of methods to isolate and detect EVs and other particles in plasma.

00:00

Dominique PV de KleijnConference Chair

Title to be Confirmed.
Dominique PV de Kleijn, Professor Experimental Vascular Surgery, Professor Netherlands Heart Institute, University Medical Center Utrecht, The Netherlands, Netherlands

00:00

Aurelio LoricoKeynote Presentation

Novel Anticancer Therapies Based on Interference with Uptake and Intracellular Distribution of Extracellular Vesicles in Recipient Cells
Aurelio Lorico, Professor of Pathology, Touro University Nevada, United States of America

The intercellular communication mediated by extracellular vesicles (EVs) plays an important role in tumor progression. In particular, cancer cell-derived EVs participate in the transformation of tumor microenvironment. Interfering with the mechanisms regulating this cellular process might find therapeutic application particularly in oncology. Here, two potentially therapeutic strategies based on interference with EV uptake and intracellular distribution will be presented. The first is based on our recent finding that silencing tetraspanin CD9 both in EVs and recipient cells strongly decreased the uptake of EVs. Analogously, monovalent Fab fragments derived from 5H9 anti-CD9 monoclonal antibody (referred hereafter as CD9 Fab) partially blocked uptake of melanoma EVs in recipient cells. To monitor the intracellular transport of proteins, we used fluorescent EVs containing CD9-green fluorescent protein fusion protein and various melanoma cell lines and bone marrow-derived mesenchymal stromal cells as recipient cells. CD9 Fab considerably reduced EV uptake in all examined cells. In contrast, the divalent CD9 antibody stimulated both events. The second strategy is based on our previous report of a new intracellular pathway where a fraction of endocytosed EV-associated proteins and nucleic acids is transported into the nucleoplasm of the host cell via a subpopulation of late endosomes penetrating into nucleoplasmic reticulum. A tripartite protein complex, containing the endoplasmic reticulum-localized protein VAP-A, the cytoplasmic oxysterol-binding protein ORP3 and late endosome-associated small GTPase Rab7 orchestrates the specific localization of late endosomes into nucleoplasmic reticulum. Silencing of VAP-A or ORP3 abrogated the association of late endosomes with nuclear envelope invaginations and the transport of endocytosed EV-derived components to the nucleoplasm of recipient cells. We now report that silencing of ORP3 or VAP-A, but not its homologue VAP-B, reverses the pro-metastatic changes induced by EVs isolated from highly metastatic cells on their non-metastatic counterpart. By impeding intercellular communication in the tumor microenvironment. CD9 Fab-mediated inhibition of EV uptake or inhibition of the EV nuclear pathway, combined with direct targeting of cancerous cells, could lead to the development of novel anti-cancer therapeutic strategies.

00:00

Lucia LanguinoKeynote Presentation

Title to be Confirmed.
Lucia Languino, Professor of Cancer Biology, Thomas Jefferson University, United States of America

00:00

Andreas MöllerKeynote Presentation

Title to be Confirmed.
Andreas Möller, Associate Professor, Group Leader and Head, Tumour Microenvironment Laboratory, QIMR Berghofer Medical Research Institute, Australia

00:00

Balaji PanchapakesanKeynote Presentation

Title to be Confirmed.
Balaji Panchapakesan, Professor, Department of Mechanical Engineering, Worcester Polytechnic Institute (WPI), United States of America

00:00

Title to be Confirmed.
Chamindie Punyadeera, Associate Professor, Institute of Health and Biomedical Innovation, Queensland University of Technology, Australia

00:00

Lorena DiéguezKeynote Presentation

Title to be Confirmed.
Lorena Diéguez, Leader of the Medical Devices Research Group, INL- International Iberian Nanotechnology Laboratory, Portugal


Agenda is not currently available
Add to Calendar ▼2020-10-19 00:00:002020-10-20 00:00:00Europe/LondonCirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2020Circulating Biomarkers, Exosomes and Liquid Biopsy Europe 2020 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com